GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (STU:ET80) » Definitions » Cyclically Adjusted Revenue per Share

AEterna Zentaris (STU:ET80) Cyclically Adjusted Revenue per Share : €26.24 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AEterna Zentaris's adjusted revenue per share for the three months ended in Mar. 2024 was €0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €26.24 for the trailing ten years ended in Mar. 2024.

During the past 12 months, AEterna Zentaris's average Cyclically Adjusted Revenue Growth Rate was -13.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -67.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -66.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AEterna Zentaris was 0.30% per year. The lowest was -67.80% per year. And the median was -20.90% per year.

As of today (2024-06-08), AEterna Zentaris's current stock price is €6.56. AEterna Zentaris's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €26.24. AEterna Zentaris's Cyclically Adjusted PS Ratio of today is 0.25.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AEterna Zentaris was 0.62. The lowest was 0.01. And the median was 0.03.


AEterna Zentaris Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for AEterna Zentaris's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Cyclically Adjusted Revenue per Share Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,925.43 666.99 332.14 212.70 27.01

AEterna Zentaris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.43 29.13 27.24 27.01 26.24

Competitive Comparison of AEterna Zentaris's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, AEterna Zentaris's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Cyclically Adjusted PS Ratio falls into.



AEterna Zentaris Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AEterna Zentaris's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.003/126.2576*126.2576
=0.003

Current CPI (Mar. 2024) = 126.2576.

AEterna Zentaris Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 1.286 98.367 1.651
201503 9.571 99.789 12.110
201506 16.000 100.500 20.101
201509 6.696 100.421 8.419
201512 0.949 99.947 1.199
201603 2.192 101.054 2.739
201606 0.859 102.002 1.063
201609 2.400 101.765 2.978
201612 2.483 101.449 3.090
201703 1.848 102.634 2.273
201706 1.532 103.029 1.877
201709 1.278 103.345 1.561
201712 0.909 103.345 1.111
201803 121.200 105.004 145.732
201806 0.878 105.557 1.050
201809 3.463 105.636 4.139
201812 6.725 105.399 8.056
201903 0.201 106.979 0.237
201906 0.994 107.690 1.165
201909 1.521 107.611 1.785
201912 0.080 107.769 0.094
202003 4.502 107.927 5.267
202006 0.255 108.401 0.297
202009 0.194 108.164 0.226
202012 3.102 108.559 3.608
202103 1.469 110.298 1.682
202106 1.085 111.720 1.226
202109 0.737 112.905 0.824
202112 0.737 113.774 0.818
202203 1.134 117.646 1.217
202206 -0.173 120.806 -0.181
202209 1.548 120.648 1.620
202212 1.929 120.964 2.013
202303 1.638 122.702 1.685
202306 1.708 124.203 1.736
202309 0.002 125.230 0.002
202312 0.091 125.072 0.092
202403 0.003 126.258 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


AEterna Zentaris  (STU:ET80) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AEterna Zentaris's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.56/26.24
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AEterna Zentaris was 0.62. The lowest was 0.01. And the median was 0.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AEterna Zentaris Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (STU:ET80) Business Description

Industry
Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

AEterna Zentaris (STU:ET80) Headlines

No Headlines